Patient enrollment completed in a Phase IIa study (NCT05938920) in China, which is investigating the safety, tolerability, and preliminary efficacy of INS018_055 for idiopathic Pulmonary Fibrosis (IPF). (IMAGE)

InSilico Medicine

Patient enrollment completed in a Phase IIa study (NCT05938920) in China, which is investigating the safety, tolerability, and preliminary efficacy of INS018_055 for idiopathic Pulmonary Fibrosis (IPF).

Caption

The randomized, double-blind, placebo-controlled study is being conducted across 29 clinical centers in China and has completed enrollment of the planned target of 71 patients in four participant groups, including three experimental and one placebo. 

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.